Focus: AVEO Oncology is a small-molecule focused biotechnology company headquartered in Boston specializing in oncology drug development. The company operates at early clinical stages with a lean pipeline in a competitive therapeutic area.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
AVEO is an early-stage bet suitable only for candidates seeking exploratory oncology roles with high technical autonomy but limited near-term stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AVEO Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AVEO Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles